DGAP-Adhoc: Alphaform AG: Alphaform resolves on a 10% capital increase

| Source: EQS Group AG
Alphaform AG  / Key word(s): Capital Increase

21.02.2014 13:37

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad-hoc release

Alphaform AG / capital increase
Alphaform resolves on a 10% capital increase

Feldkirchen, 21 February 2014 - The Management Board of the 3D printing
service provider Alphaform AG, with the approval of the Supervisory Board
and based on authorised capital under the Articles of Association, today
resolved to increase the share capital in exchange for cash contributions.
The increase is of EUR 531,791.00 from EUR 5,318,209.00 to EUR 5,850,000.00
and is to be implemented by issuing 531,791 no-par value bearer shares at a
notional value of EUR 1.00 per share with a profit-sharing entitlement from
1 January 2013. The shareholders' subscription rights are excluded in the
context of the capital increase.

The new shares will largely be assumed by an institutional investor as part
of a private placement at a placement price of EUR 3.40 per share. The
company is likely to receive a total of EUR 1.8 million.

The new shares are to be admitted to trading on the stock exchange without
a listing prospectus and included in the existing listing in the Prime
Standard segment of the regulated market on the Frankfurt stock exchange.

Dr. Thomas Vetter
Kapellenstraße 10
85622 Feldkirchen

Tel.: +49 89 905002 21
Fax: +49 89 9050021021
e-mail: tvetter@alphaform.de 
Internet: www.alphaform.de


Information and Explaination of the Issuer to this News:

About Alphaform

Alphaform AG, based in Feldkirchen near Munich was founded in 1996. The
company belongs to the European market leaders in the production of complex
components means additive manufacturing, which are often grouped together
under the term '3D printing'. An important mainstay of the segment 3D
Printing and Additive Manufacturing is the production of series close
prototypes, particularly for the automotive and capital goods industries.
The Medical Division of Alphaform has a leading position throughout Europe
in manufacturing and processing orthopaedic implants and instruments. The
shares of Alphaform are listed in the Prime Standard Segment of the
Frankfurt Stock Exchange (FWB) under the abbreviation ATF.

The core competence of Alphaform lies in its extensive application know-how
for processes and materials for the additive production of complex
prototypes, tools, individual components and small series made of plastic
and metal. The company's activity is focused on the orthopaedic and medical
technology, automotive, aviation and aerospace industries. The subsidiaries
of Alphaform are located in Germany, Finland, Sweden and the UK.

21.02.2014 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language:     English
Company:      Alphaform AG
              Kapellenstraße 10
              85622 Feldkirchen
Phone:        +49 (0)89 905002 - 0
Fax:          +49 (0)89 905002 - 90
E-mail:       ir@alphaform.de
Internet:     www.alphaform.de
ISIN:         DE0005487953
WKN:          548795
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, München, Stuttgart
End of Announcement                             DGAP News-Service